DDIT3 and cancer: By applying larger panels of genes, including the Pan Cancer Immune Profiling one, we observed that the expression of genes other than those related to the COO can represent additional relevant prognosticators (e.g.BCL2 andMYC) in DLBCLs treated with R-CHOP/R-CHOP-like therapies.